TS-075238 — Problem Low titer group O whole blood (LTOWB) is the gold standard used by the US military to treat blood loss. However, there is a limited supply with ex vivo storage and shelf-life limitations. There is no whole blood substitute on the market when LTOWB is not available. Solution Dr. Andre Palmer and team have developed several whole blood substitute formulations to mimic the 3 main functions of whole blood: 1) oxygen transport (provided by hemoglobin-based oxygen carrier [HBOC]); 2) clotting (provided by tranexamic acid); and 3) volume replacement (provided by a plasma substitute). The HBOC consists of T-state polymerized human hemoglobin (PolyhHb). The clotting agent consists of tranexamic acid (TXA). The volume replacement solution consists of polymerized human serum albumin (PolyHSA). Additional additives include high molecular weight polyethylene glycol as a drag reducing agent, and dexamethasone as an anti-inflammatory agent. Applications Prehospital and austere environments Used by EMS and military for early resuscitation before hospital arrival Hospital trauma protocols Used for first-line transfusion in exsanguinating patients Advantages Mimics the three major functions of whole blood without the risk of blood type incompatibility and disease transmission Extended shelf life versus whole blood Scalable production Seeking opportunities for out-licensing and collaboration

TS-075233 — Problem Transducin β-like protein 1 (TBL1) has emerged as a promising therapeutic target in oncology, due to its central role in regulating multiple oncogenic signaling pathways. The challenge is how to develop a selective and effective inhibitor of TBL1 with high efficacy and limited side-eff…

TS-075175 — Problem Idiopathic pulmonary fibrosis (IPF) is a chronic disease where activated fibroblasts mediate the abnormal accumulation of extracellular matrix (ECM) in the lung interstitial space, leading to progressive impairment of pulmonary function. Current IPF therapies are associated with significant…

TS-071830 — Unlocking plant-powered solutions to deliver effective inflammation relief and enhance disease outcomes.

TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.

TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.

TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…

TS-062571 — The Need Coral reefs are declining at an alarming rate. When temperatures increase by as little as 1-2 °C above their normal thermal maximum for as little as ten days, corals become stressed, lose their endosymbiotic algae, and turn white – hence the term bleaching. When bleached, corals…

TS-062322 — The Need The field of molecular biology faces a critical commercial need in the effective diagnosis, treatment, and prevention of cancer-related disorders associated with mismatch repair (MMR) dysfunction. Diseases such as Lynch Syndrome (LS) and hereditary non-polyposis colorectal cancer (HNPCC), …

TS-062306 — The Need Ovarian cancer is a significant health concern, being the leading cause of gynecological cancer-related deaths in the developed world. Current treatments, such as platinum-based chemotherapy, have limited success due to issues like late-stage diagnosis and chemoresistance. Identifying mole…